Edition:
United States

Portola Pharmaceuticals Inc (PTLA.OQ)

PTLA.OQ on NASDAQ Stock Exchange Global Select Market

39.94USD
4:00pm EDT
Change (% chg)

$0.02 (+0.05%)
Prev Close
$39.92
Open
$40.01
Day's High
$40.14
Day's Low
$39.66
Volume
116,957
Avg. Vol
408,403
52-wk High
$66.93
52-wk Low
$30.10

Summary

Name Age Since Current Position

Hollings Renton

71 2010 Independent Chairman of the Board

Mardi Dier

54 2018 Interim Co-President, Chief Financial Officer, Executive Vice President

John Curnutte

66 2018 Interim Co-President, Executive Vice President Research and Development

William Lis

53 2010 Chief Executive Officer, Director

John Moriarty

50 2018 Executive Vice President, General Counsel

Tao Fu

46 2015 Executive Vice President, Chief Commercial and Business officer

John Lawrence

60 2017 Senior Vice President, Chief Medical Officer

Jeffrey Bird

57 2003 Independent Director

Laura Brege

60 2015 Independent Director

Dennis Fenton

66 2015 Independent Director

Charles Homcy

69 2013 Independent Director

John Johnson

60 2014 Independent Director

David Stump

68 2015 Independent Director

H. Ward Wolff

69 2007 Independent Director

Biographies

Name Description

Hollings Renton

Mr. Hollings C. Renton, III is the Independent Chairman of the Board of the Company. He has served as a member and the Chairman of our Board since March 2010. Mr. Renton retired as Chairman of the Board of Directors at Onyx Pharmaceuticals, in March 2008, where he also served as the President and Chief Executive Officer from 1993 and as a director from 1992. From 1991 to 1993, he served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation, a biotechnology company. Prior to the acquisition, he served as President of Cetus Corporation from 1990 to 1991, as Chief Operating Officer from 1987 to 1990, and as Chief Financial Officer from 1983 to 1987. Mr. Renton currently serves as a member of the Boards of Directors of AnaptysBio, Inc. and Zymeworks Inc. During the past five years, Mr. Renton also served on the Boards of Directors of Kythera Biopharmaceuticals Inc., Rigel Pharmaceuticals, Inc., Affymax Inc. and Cepheid Inc. Mr. Renton holds a B.S. in Mathematics from Colorado State University and an M.B.A. from the University of Michigan. Because of Mr. Renton’s extensive experience building successful biotechnology companies and commercializing drug products, we believe he is able to bring valuable insights to our Board, Compensation Committee, Nominating and Corporate Governance Committee and Commercial Committee.

Mardi Dier

Ms. Mardi C. Dier is Interim Co-President, Chief Financial Officer, Executive Vice President of the Company. She has served as our Executive Vice President and Chief Financial Officer since August 2006. From June 2003 to July 2006, Ms. Dier served as Vice President of Investor Relations at Chiron Corporation, a biopharmaceutical company. From 1994 to 2001, Ms. Dier served as a Director, Investment Banking at Prudential Securities, Inc., a securities firm. Since July 2014, Ms. Dier has served as a director of Jewish Vocational Service, a nonprofit organization. Ms. Dier previously was a supervising senior accountant at the audit department of KPMG LLP, an accounting firm, from 1986 to 1990. Ms. Dier holds a B.S. in Biology from Stanford University and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.

John Curnutte

Dr. John T. Curnutte, M.D., Ph.D., is Interim Co-President, Executive Vice President Research and Development of the Company. He has served as our Executive Vice President of Research and Development since February 2011. From May 2015 to June 2016, Dr. Curnutte served as a member of the Board of Directors of Diadexus, Inc., a medical diagnostics company. From April 2010 to January 2011, Dr. Curnutte served as an independent consultant. From May 2008 to March 2010, Dr. Curnutte served as the Chief Executive Officer of 3-V Biosciences, Inc., a biotechnology company. From September 2000 to May 2008, he served as President of Schering-Plough Biopharma, a biopharmaceutical subsidiary of Schering-Plough Corporation, and Senior Vice President of Discovery Research at Schering Plough Research Institute, a pharmaceutical and healthcare company. From August 1993 to September 2000, Dr. Curnutte held various senior management positions at Genentech, Inc., a biotechnology company. Dr. Curnutte was an adjunct clinical professor of pediatrics at the Stanford University School of Medicine and a member of the medical staff from 1993 to 2013. Dr. Curnutte holds an A.B. in Biochemistry and Molecular Biology from Harvard University and an M.D. and a Ph.D. in Biological Chemistry from Harvard Medical School.

William Lis

Mr. William (Bill) Lis no longer serves as Chief Executive Officer and Director of the Company, effective as of August 1, 2018. Mr. Lis served as our Chief Executive Officer and a member of our Board since April 2010. Mr. Lis served as our Chief Operating Officer from November 2009 to April 2010, as our Vice President of Business and Commercial Operations from May 2008 to October 2009 and as our Senior Director of Business Development from May 2005 to August 2005. Prior to Portola, Mr. Lis held various management positions at Scios Inc., a biotechnology company and a subsidiary of Johnson & Johnson, a medical devices, pharmaceutical and consumer packaged goods company, including Vice President Business and Commercial Operations from November 2007 to April 2008, Vice President of Business and New Product Development from August 2005 to November 2007 and Director of Cardiovascular Marketing and New Products from January 2004 to May 2005. From November 2003 to December 2003, Mr. Lis served as a consultant to Biosite Incorporated, a medical diagnostics company, and to Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Following the acquisition of COR Therapeutics, by Millennium in 2002, he held various positions, including Director, Marketing and New Product Development from February 2002 to November 2003. From October 1999 to February 2002, Mr. Lis held various positions, including Product Director, at COR Therapeutics. Mr. Lis holds a B.S. in Business Management and Finance from the University of Maryland, College Park.

John Moriarty

Mr. John B. Moriarty, J.D., is Executive Vice President, General Counsel of the Company. Mr. Moriarty has served as our Executive Vice President and General Counsel since March 2018. Mr. Moriarty served as Executive Vice President and General Counsel of Alexion Pharmaceuticals, Inc. from September 2014 to February 2018, and served as Senior Vice President and General Counsel of Alexion from December 2012 to September 2014. He has served on the board of trustees for the American Kidney Fund since 2015. From March 2010 to December 2012, Mr. Moriarty served as General Counsel and Chief Legal Officer at Elan Corporation plc, an Irish public limited company traded on the New York and Irish Stock Exchanges, and also served as a member of Elan’s Executive Management team. From December 2008 to March 2010, Mr. Moriarty served as Senior Vice President of Law, Litigation and Commercial Operations at Elan. From 2002 to 2008, Mr. Moriarty held various positions with Amgen, Inc., including Executive Director and Associate General Counsel, Global Commercial Operations - Amgen Oncology and Senior Counsel, Complex Litigation, Products Liability and Government Investigations. Between 1994 and 2002, Mr. Moriarty served in various capacities in private legal practice focused on healthcare and as a healthcare fraud prosecutor in the U.S. Attorney’s Office and the Virginia Attorney General’s Office. Mr. Moriarty holds a B.A., with distinction, from the University of Virginia and a J.D., cum laude, from the University of Georgia School of Law.

Tao Fu

Mr. Tao Fu is the Executive Vice President, Chief Commercial and Business officer of the Company. Mr. Fu has served as our Executive Vice President and Chief Commercial and Business Officer since June 2015. From January 2014 to June 2015, Mr. Fu served as Vice President and Head of Mergers and Acquisitions and Alliance Management at Bristol-Myers Squibb, a biopharmaceutical company. From March 2010 to January 2014, Mr. Fu served as Vice President, Business Development, Head of Mergers and Acquisitions at Janssen Pharmaceuticals, Inc., the pharmaceuticals group of Johnson & Johnson. From September 2006 to March 2010, he served as Vice President, Business Development at Janssen. From 2002 to 2006, Mr. Fu served as Vice President, Business Development at Scios Inc., a biopharmaceutical company (acquired by Johnson & Johnson). From 2001 to 2002, Mr. Fu served as a Consultant at McKinsey & Company, a management consulting firm. Mr. Fu previously was a Manager, Business Development at Becton, Dickinson and Company, a medical technology company, from 1997 to 2000. Mr. Fu serves on the Board of Directors of Zai Lab Limited, a biopharmaceutical company. Mr. Fu is also a chartered financial analyst. Mr. Fu completed his undergraduate studies at Tsinghua University, holds an M.S. in Biology from the University of Rochester and an M.B.A from the Owen Graduate School of Management at Vanderbilt University.

John Lawrence

Dr. John H. (Jack) Lawrence, M.D., has been Senior Vice President and Chief Medical Officer of Portola Pharmaceuticals, Inc. since November 2017. From March 1999 to October 2017, Dr. Lawrence was with Bristol-Myers Squibb (BMS), a biopharmaceutical company, where he held positions of increasing responsibility in the company’s cardiovascular division, most recently Vice President and cardiovascular therapeutic area head with responsibility for global clinical development and regulatory activities of the Factor Xa inhibitor, apixaban. Dr. Lawrence holds an M.D. from the University of Virginia, and completed his cardiology fellowship training at The Johns Hopkins University School of Medicine, where he later served as an associate professor. Dr. Lawrence holds a B.S. in Biomedical Engineering from Brown University and an M.S. in Electrical Engineering from the Massachusetts Institute of Technology.

Jeffrey Bird

Dr. Jeffrey W. Bird, M.D. Ph.D. is an Independent Director of the Company. He has served as a member of our Board since November 2003. Since July 2003, Dr. Bird has been a Managing Director of Sutter Hill Ventures, a venture capital firm. Dr. Bird currently serves as a member of the Board of Directors of Restoration Robotics, Inc., a medical device company. During the last five years, Dr. Bird also served on the Boards of Directors of Threshold Pharmaceuticals, Inc. and Horizon Pharma Public Limited Company. Dr. Bird holds a B.S. in Biological Sciences from Stanford University and a Ph.D. in Cancer Biology and an M.D. from Stanford Medical School. Because of Dr. Bird’s experience in medicine and biology, and because of his experience investing in life science companies and serving as an executive at biopharmaceutical companies, we believe he is able to bring important insights to our Board, Audit Committee and Research and Development Committee.

Laura Brege

Ms. Laura A. Brege is an Independent Director of the Company. She has served as a member of our Board since January 2015. Since September 2015, Ms. Brege has served as Managing Director of Cervantes Life Science Partners, LLC, a private healthcare advisory and consulting company focused on innovative personalized medicine. From July 2017, Ms. Brege has served as a Senior Advisor to Bridge Bio Pharma, a clinical stage biotechnology company. From September 2012 to July 2015, Ms. Brege served as Chief Executive Officer and President of Nodality, Inc., a company focused on innovative personalized medicine. From June 2006 to December 2011, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, including Executive Vice President and Chief Operating Officer. From 1999 to 2006, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm. Prior to Red Rock, she was the Senior Vice President and Chief Financial Officer at COR Therapeutics. Ms. Brege currently serves as a member of the Boards of Directors of Acadia Pharmaceuticals, Inc., Aratana Therapeutics, Inc., Dynavax Technologies, Inc., and Pacira Pharmaceuticals, Inc. During the past five years, Ms. Brege also served on the Board of Directors of Delcath Systems, Inc. Ms. Brege holds a B.A. from Ohio University (Honors Tutorial College) and an M.B.A. from the University of Chicago. We believe that Ms. Brege’s industry background, including her extensive experience as an officer of public biotechnology companies and her past financial experience and current knowledge of financing trends, position her to make an effective contribution to our Board, Audit Committee and Commercial Committee.

Dennis Fenton

Dr. Dennis M. Fenton, Ph.D. is an Independent Director of the Company. He has served as a member of our Board since February 2015. Dr. Fenton is the owner and Chief Executive Officer of Fenton and Associates, a biotechnology consulting firm. From 1982 to 2008, Dr. Fenton held numerous positions at Amgen, Inc., a biotechnology company. From 2000 until 2008, Dr. Fenton was Executive Vice President responsible for worldwide operations, manufacturing, process development and quality. From 1995 until 2000, Dr. Fenton was Senior Vice President of Operations, and from 1992 until 1995, he was Senior Vice President of Sales, Marketing and Process Development. Prior to his time at Amgen, Inc., Dr. Fenton served as Senior Research Scientist at Pfizer, Inc., a biopharmaceutical company, and previously was a research associate and graduate student at Rutgers University. Dr. Fenton currently serves as a member of the Board of Directors of Pfenex Inc., a biopharmaceutical company, through May 2018, and also serves as a member of the Boards of Directors of AnaptysBio, Inc., a biotechnology company, and Sienna Biopharmaceuticals, Inc., a biopharmaceutical company. Dr. Fenton is also a member of the Board of Trustees of Keck Graduate Institute. During the past five years, Dr. Fenton also served on the Board of Directors of Xenoport, Inc., Dendreon Corporation, Hospira, Inc., Genelux Corporation, Amira Pharmaceuticals and Kythera Biopharmaceuticals, Inc. Dr. Fenton holds a B.S. in Biology from Manhattan College and a Ph.D. in Microbiology from Rutgers University. Because of Dr. Fenton’s extensive experience in development, operations and biologics manufacturing, we believe he is able to make valuable contributions to our Board, Compensation Committee and Research and Development Committee.

Charles Homcy

Dr. Charles J. Homcy, M.D. is an Independent Director of the Board of the Company. He has served as a member of our Board since September 2003, as Co-Chairman of our Board from March 2010 to May 2013 and as Chairman of our Board from September 2003 to March 2010. Dr. Homcy presently is a partner at Third Rock Ventures, a venture capital firm. Dr. Homcy served as a Venture Partner of Third Rock Ventures from 2010 to 2016. From 1997 through 2008, Dr. Homcy has served as Clinical Professor of Medicine, University of California at San Francisco Medical School and as an attending physician at the San Francisco Veteran’s Administration Hospital. Dr. Homcy is a co-founder of Portola and served as President and Chief Executive Officer of Portola from September 2003 to April 2010 and was employed as an adviser to Portola from May 2010 to February 2012. Dr. Homcy served as President, Research and Development at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, from February 2002 to January 2003 and senior adviser of Research and Development at Millennium from January 2003 to November 2003. From May 1995 to March 2002, Dr. Homcy served as Executive Vice President of Research and Development of COR Therapeutics, Inc., a biopharmaceutical company. Dr. Homcy currently serves as a member of the Boards of Directors of Global Blood Therapeutics, Inc. and Pliant Therapeutics, Inc., and is a member of the Board of Trustees of Johns Hopkins University. During the past five years, Dr. Homcy also served on the Board of Directors of MyoKardia, Inc., a biopharmaceutical company. Dr. Homcy also serves as a Scientific Advisor for Cytokinetics, Inc. Dr. Homcy holds an A.B. in Biology and an M.D. from Johns Hopkins University. Dr. Homcy is also a member of the Board of Trustees of John Hopkins University. Because of Dr. Homcy’s executive experience with the Company and in the life sciences industry, we believe he is able to make valuable contributions to our Board, and Research and Development Committee.

John Johnson

Mr. John H. Johnson is an Independent Director of the Company. He has served as a member of our Board since March 2014. From January 2012 until August 2014, Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation, a biopharmaceutical company, and their Chairman from January 2012 until June 2014. From January 2011 until January 2012, he served as the Chief Executive Officer and a member of the Board of Directors of Savient Pharmaceuticals, Inc., a pharmaceutical company. From November 2008 until January 2011, Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company’s Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008, and served on ImClone’s Board of Directors until it was acquired by Eli Lilly in November 2008. From 2005 to August 2007, Mr. Johnson served as Company Group Chairman of Johnson & Johnson’s Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada unit from 2003 to 2005, and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., Ortho-McNeil Pharmaceutical Corporation and Pfizer, Inc. Mr. Johnson is the former chairman of Tranzyme Pharma, Inc. Mr. Johnson currently serves as a member of the Boards of Directors of Histogenics Corporation, Melinta Therapeutics, Inc., a biopharmaceutical company, and Aveo Oncology, and is chairman of Strongbridge Biopharma plc, a biopharmaceutical company. During the past five years, Mr. Johnson also served as a member of the Boards of Directors of Sucampo Pharmaceuticals, Inc. and Cempra, Inc. Mr. Johnson holds a bachelor’s degree from East Stroudsburg University of Pennsylvania.

David Stump

Dr. David Carter Stump, M.D. is an Independent Director of the Company. He has served as a member of our Board since September 2015. Dr. Stump was most recently Executive Vice President, Research and Development at Human Genome Sciences, Inc., serving there from November 1999 until December 2012. From 1989 to 1999, Dr. Stump held various roles at Genentech, Inc., most recently as Vice President, Clinical Research, and was named a Genentech Fellow in 1996. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump currently serves as a member of the Boards of Directors of Regenxbio, Inc., Sunesis Pharmaceuticals, Inc. and MacroGenics, Inc. During the past five years, Dr. Stump also served on the Board of Directors of Dendreon Corporation. Dr. Stump is also a member of the Board of Trustees of Earlham College. Dr. Stump is board certified in Internal Medicine, Hematology and Medical Oncology, and is a Fellow of the American College of Physicians and the Council on Arteriosclerosis, Thrombosis and Vascular Biology of the American Heart Association. He holds an A.B. from Earlham College and an M.D. from Indiana University, followed by residency and fellowship training in internal medicine, hematology and oncology and biochemistry at the University of Iowa, then by further postgraduate training in hemostasis and thrombosis at the University of Leuven, Belgium. Because of Dr. Stump’s extensive medical and scientific background and executive experience in the life sciences industry, we believe he is able to make valuable contributions to our Board, Nominating and Corporate Governance Committee and Research and Development Committee.

H. Ward Wolff

Mr. H. Ward Wolff is an Independent Director of the Company. He has served as a member of our Board since November 2007. From December 2007 until his retirement in March 2017, Mr. Wolff served as Executive Vice President and Chief Financial Officer of Sangamo Therapeutics, Inc., a biopharmaceutical company. From July 2006 until its restructuring in August 2007, Mr. Wolff served as the Senior Vice President, Finance and Chief Financial Officer of Nuvelo, Inc., a biopharmaceutical company. From September 2004 to April 2006, Mr. Wolff was Senior Vice President, Finance and Chief Financial Officer of Abgenix, Inc., a biopharmaceutical company. Prior to joining Abgenix, Mr. Wolff held financial management positions in both public and private emerging growth companies, including serving as Senior Vice President and Chief Financial Officer of DoubleTwist, Inc., a life sciences company. Mr. Wolff began his career with Price Waterhouse, where he held a number of positions as a certified public accountant, including Senior Audit Manager. Mr. Wolff currently serves as a member of the Boards of Directors of Calithera Biosciences, Inc. and Sunesis Pharmaceuticals, Inc. During the past five years, Mr. Wolff served on the Board of Directors of MAP Pharmaceuticals, Inc. Mr. Wolff holds a B.A. in Economics from the University of California at Berkeley and an M.B.A. from Harvard Business School. Because of Mr. Wolff’s management experience in several public companies, we believe he is able to bring financial expertise to our Board and Audit Committee.

Basic Compensation

Name Fiscal Year Total

Hollings Renton

321,007

Mardi Dier

2,467,460

John Curnutte

2,133,050

William Lis

4,885,800

John Moriarty

--

Tao Fu

2,399,440

John Lawrence

4,079,790

Jeffrey Bird

284,507

Laura Brege

284,507

Dennis Fenton

281,007

Charles Homcy

289,007

John Johnson

309,007

David Stump

279,507

H. Ward Wolff

289,007
As Of  30 Dec 2017

Options Compensation